19 October-30 November 2020
The 51st Union World Conference On Lung Health


EP36-Molecular testing for TB infection and drug resistance
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP36-Molecular testing for TB infection and drug resistance
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP36-445-24-Effect of switching from Xpert® MTB/RIF to Xpert® MTB/RIF-Ultra on tests done and TB cases diagnosed in Uganda: a case of assay superiority?This switch was supposed to give us more tests with an increased sensitivity of 12%-17%. Our study did not find this. We hypothesis that, if the health systems approach had been taken during the switch, all the potential benefits of the new assay would have been realised.
Michael Kakinda

EP36-446-24-Factors associated with drug-resistant TB among prisoners in Sāo Paulo State, BrazilThis study investigated the determinants of drug-resistant tuberculosis (DR-TB) among prisoners in the state of São Paulo, Brazil. It involved a retrospective cohort of DR-TB cases among prisoners. Sputum smear and culture, chest X-ray, AIDS, alcoholism and background treatment history for TB, were determinants associated with resistance to anti-TB drugs among prisoners.
Ricardo Arcêncio

EP36-447-24-Did expansion of GeneXpert machines find missing TB patients? Experience from NigeriaFrom commencement of GeneXpert implementation in 2011 to 2019, 407 GeneXpert machines (less than 45% geographical coverage across 774 local government areas) were installed in Nigeria. Starting from 2017, the TB programme shifted emphasis to GeneXpert service optimisation (47% utilisation rate) and halted installation of more machines.

Sani Useni

EP36-448-24-Xpert MTB/RIF Ultra improved the diagnosis of tuberculous meningitis in HIV-negative patients: a prospective studyThe role of Xpert MTB/RIF Ultra (Xpert Ultra) in diagnosing tuberculous meningitis(TBM) is uncertain. Implementation of Xpert Ultra in different epidemiological and geographical settings with different patient populations, might gain different benefits. We evaluated the performance of Xpert Ultra for TBM diagnosis in HIV-negative patients in China.
Mailing Huang

EP36-449-24-Hypothetical yield of serial TB screening using Xpert MTB/RIF among people living with HIV in Kampala, UgandaRoutine intensified case finding (ICF) for tuberculosis is recommended for people with HIV in TB-endemic areas, but its yield is unclear. We compared the estimated yield of two strategies - 1. baseline ICF with culture and Xpert, plus three-month ICF with Xpert only, and 2. baseline and three-month ICF with Xpert only.
Lelia Chaisson

EP36-450-24-Prevalence of gene mutations profiles by GenoType MTBDRplus in isoniazid Mycobacterium tuberculosis-resistant strains, Tunisia 2015-2019Mutations in katG and inhA promotor are involved respectively in 93.2% and 21.4% of isoniazid resistant M. tuberculosis strains. 
The aim of this study is to determine the genetic profiles of isoniazid-resistant M. tuberculosis strains in Tunisia during 2015-2019, using the molecular assay, GenoType MTBDRplus V2.0
Imen Bouzouita

EP36-451-24-Evaluation of BD MAX multidrug-resistant TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with rifampicin and isoniazid resistanceEmergence of multidrug resistance in Mycobacterium tuberculosis complex (MTBC) and the length of time to diagnosis, are challenges to global tuberculosis control. New technologies, such as BD MAX MDR-TB, offer faster time to diagnosis, allowing effective treatment without a delay. We assessed suitability of the assay for use in the clinical setting.
Seb Cotton

EP36-452-24-Culture positivity rates among rifampicin-resistant indeterminate patients tested using Xpert® MTB/RIF-Ultra in high TB-HIV care settings: Uganda case studyThe World Health Organization recommends additional testing using culture and drug susceptibility testing (DST) methods for all patients initially tested with the Xpert® MTB/RIF-Ultra technique, and whose rifampicin resistance pattern is indeterminate. We determined the culture positivity rates among 75 rifampicin-resistant indeterminate patients in high TB-HIV care settings.
Didas Tugumisirize

EP36-453-24-A novel standardised artificial sputum for external quality control of the whole TB diagnostic workflowCurrently there is no validated test matrix for externally monitoring the quality of sputum-based TB diagnostics (EQA) including smear-microscopy, culture and molecular testing. We have developed a novel mucin-based artificial sputum (MUCAS) suitable for EQA panels assessing the performance of Ziehl-Neelsen microscopy, mycobacterial culture and molecular diagnostics.
Markus Beutler

EP36-454-24-The sensitivity and specificity of Xpert MTB/RIF Ultra in an active TB case finding setting and understanding the 'trace call' resultThe GeneXpert Ultra is a recent development in tackling the limitations of the MTB/Rif assay for diagnosis of paucibacillary tuberculosis. Interpretation of the 'trace call' result is a challenge, especially when used in an active case finding setting. What is new about the Xpert Ultra and the 'trace call' result?
Lophina Chilukutu

Processing. Please wait.